Kalkan, RasimeAtli, Emine Ikbal2024-06-122024-06-1220161045-44032162-6502https://doi.org/10.1615/CritRevEukaryotGeneExpr.2016015964https://hdl.handle.net/20.500.14551/22492miRNAs are short noncoding RNA sequences that cause translational repression or mRNA degradation. A growing number of studies have sought new biomarkers in GBM that will be important in disease progression and prognosis and as potential therapeutic targets. miRNA-profiling studies in glioblastoma patients have found that aberrant miRNA expression can be used as a target to develop new biomarkers for disease detection and for determining prognosis or therapeutic response. In evaluating the tumor or its therapeutic response, genetic abnormalities such as mutations, epigenetic abnormalities, and aberrant miRNA expressions can be useful markers. This review summarizes the known miRNAs according their therapeutic importance and their use as disease progression biomarkers.en10.1615/CritRevEukaryotGeneExpr.2016015964info:eu-repo/semantics/closedAccessMirnaGBMGlioblastomaTherapySurvivalMir-21 ExpressionMicrornasCancerCellsHsa-Mir-181bAstrocytomaBiomarkersSurvivalGliomasGrowthArticle262137142Q3WOS:0003807781000042-s2.0-8497990307127480776Q4